title: [Solitary and extramedullary plasmocytoma in the head and neck region: five cases report].
abstract: OBJECTIVE
  To assess the outcome and the management of solitary extramedullary plasmocytoma in the head and neck region.
  
  
  METHODS
  From 1997 to 2008, five cases of solitary extramedullary plasmocytoma were treated in the department of radiotherapy at Salah-Azaiz Institute. Three patients had a solitary plasmocytoma of the nasal fossa; the others were ethmoidal and submandibular node. All patients received irradiation of 40 to 45 Gy in the primary site associated to surgery in four cases. Among the five patients, two had radiotherapy after recurrence.
  
  
  RESULTS
  Four complete responses were noted with a follow-up of 12, 36, 52 and 72 months. Multiple myeloma occurred in one patient 8 years after treatment.
  
  
  CONCLUSIONS
  Radiotherapy is the best effective local treatment. Local control of extramedullary plasmocytoma in the head and neck region seems to be improved when the dose is at least 45 Gy. Predictive parameters of unfavourable outcome and conversion of extramedullary plasmocytoma to multiple myeloma should be better defined.
authors.affiliation: Service de radiothérapie carcinolologique, institut Salah-Azaiz, boulevard du 9-avril, 1006 Bab Saadoun, Tunis, Tunisie. chiraz ammar@yahoo.fr
authors.forename: C
authors.initials: C
authors.lastname: Nasr Ben Ammar
authors.forename: I
authors.initials: I
authors.lastname: Ghorbel
authors.forename: L
authors.initials: L
authors.lastname: Kochbati
authors.forename: W
authors.initials: W
authors.lastname: Gargouri
authors.forename: S
authors.initials: S
authors.lastname: Touati
authors.forename: M
authors.initials: M
authors.lastname: Maalej
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D005004:Ethmoid Bone / Q000473:pathology / Q000601:surgery; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D008297:Male; D008441:Maxillary Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000532:radiotherapy; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D009669:Nose Neoplasms / Q000532:radiotherapy / Q000601:surgery; D010954:Plasmacytoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012074:Remission Induction; D012888:Skull Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents